Kadmon Holdings, Inc.,(NYSE:KDMN) is a biopharmaceutical company working in small molecules and biologics space for application in autoimmune and fibrotic, oncology, and genetic diseases. The company offers a portfolio of branded generic ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including those indicated for the management of rare diseases. The firm's lead product candidates include KD025, a rho-associated coiled-coil kinase2 inhibitor, which is in Phase II clinical studies for the treatment of autoimmune, fibrotic, and neurodegenerative diseases; Tesevatinib, an oral tyrosine kinase inhibitor that is in Phase II clinical studies for use in the treatment of non-small cell lung cancer and glioblastoma, as well as for treating autosomal dominant polycystic kidney disease; and KD034 that is used for the treatment of Wilson's disease, a genetic liver disease. Kadmon Holdings, Inc. has a strategic collaborations and license agreements with a wide range of entities foreign and domestic
